Regulus Therapeutics Inc. (NASDAQ:RGLS) Downgraded to “Neutral” at Chardan Capital
Several other research firms also recently commented on RGLS. ValuEngine downgraded Regulus Therapeutics from a sell rating to a strong sell rating in a research report on Friday, June 2nd. BMO Capital Markets reissued a hold rating on shares of Regulus Therapeutics in a research report on Monday, May 15th. Wedbush reissued an ourperform rating and set a $6.00 price target on shares of Regulus Therapeutics in a research report on Tuesday, June 13th. Finally, Zacks Investment Research raised Regulus Therapeutics from a hold rating to a buy rating and set a $1.00 price target on the stock in a research report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $3.92.
Regulus Therapeutics (NASDAQ RGLS) traded down 7.0693% during trading on Wednesday, hitting $0.9386. The company had a trading volume of 2,181,360 shares. The stock has a 50-day moving average of $1.00 and a 200 day moving average of $1.35. The company’s market capitalization is $97.41 million. Regulus Therapeutics has a one year low of $0.86 and a one year high of $3.92.
Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.10. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 145.40%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Equities analysts forecast that Regulus Therapeutics will post ($1.06) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Regulus Therapeutics Inc. (NASDAQ:RGLS) Downgraded to “Neutral” at Chardan Capital” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/03/regulus-therapeutics-inc-nasdaqrgls-downgraded-to-neutral-at-chardan-capital.html.
In other Regulus Therapeutics news, Director William H. Rastetter bought 274,725 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was purchased at an average cost of $0.91 per share, for a total transaction of $249,999.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Daniel R. Chevallard bought 54,945 shares of the business’s stock in a transaction on Tuesday, July 25th. The shares were acquired at an average price of $0.91 per share, with a total value of $49,999.95. Following the completion of the purchase, the chief financial officer now directly owns 59,415 shares of the company’s stock, valued at $54,067.65. The disclosure for this purchase can be found here. Insiders have purchased 549,450 shares of company stock worth $500,000 in the last three months. 4.80% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. Teachers Advisors LLC boosted its position in Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 9,804 shares in the last quarter. Wedbush Securities Inc. boosted its position in Regulus Therapeutics by 10.3% in the second quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 18,600 shares in the last quarter. Tudor Investment Corp ET AL boosted its position in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 61,373 shares in the last quarter. Wells Fargo & Company MN boosted its position in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 93,295 shares in the last quarter. Finally, LMR Partners LLP bought a new position in Regulus Therapeutics during the second quarter worth $164,000. Hedge funds and other institutional investors own 38.53% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Stock Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related stocks with our FREE daily email newsletter.